Professor Andrew Wilson
PBAC Chair
MDP 952
Office of Health Technology Assessment Branch Department of Health

GPO Box 9848 CANBERRA ACT 2601

27 August 2018

Dear Professor Wilson,

Re: The Brain Cancer Group – From Care2Cure (Not-for-Profit) endorsement of PBAC listing of bevacizumab on the PBS for the treatment of relapsed glioblastoma (Grade IV glioma, GBM).

The Brain Cancer Group (TBCG) is a collaborative, multi-disciplinary team of leading brain cancer specialists. We apply insights from frontline patient care to inform activities across research, support and education to help improve outcomes of those affected by primary brain cancer. It is in this capacity that we endorse the expert recommendation from leading senior Australian neuro-oncologists to have bevacizumab listed on the PBS for the treatment of relapsed glioblastoma.

As a Group who have funded dedicated Neuro-Oncology Care Coordinators for over 10 years, we have an intimate connection to a range of primary brain cancer patients. This close insight has identified concerning variation in clinical care.

> *"It is frustrating to see patient treatment vary due to financial capacity.*
> *This is currently the case for primary brain cancer patients"*
> Marina Kastelan, Neuro Oncology Nurse Practitioner, The Brain Cancer Group,
> speaking specifically on the varying patient access to bevacizumab

Whilst I defer to the opinion of the expert neuro-oncologists on the clinical rationale behind a listing of bevacizumab, I can however endorse the proposal on the basis of improving patient outcomes for all patients, regardless of financial means. A brain cancer diagnosis is devastating to patients and their families, financially and emotionally, we should be doing all that we can to reduce this devastation.

Kind Regards,

Mr Pat Wheaton - CEO
The Brain Cancer Group
"From Care2Cure"